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SUMMARY
Among the causes of lymphoedema (LE), secondary LE
due to filariasis is the most prevalent. It affects only a
minority of the 120 million people infected with the causa-
tive organisms of lymphatic filariasis (LF), Wuchereria
bancrofti and Brugia malayi⁄timori, but is clustered in
families, indicating a genetic basis for development of this
pathology. The majority of infected individuals develop filar-
ial-specific immunosuppression that starts even before birth
in cases where mothers are infected and is characterized by
regulatory T-cell responses and high levels of IgG4, thus tol-
erating high parasite loads and microfilaraemia. In contrast,
individuals with this pathology show stronger immune reac-
tions biased towards Th1, Th2 and probably also Th17.
Importantly, as for the aberrant lymph vessel development,
innate immune responses that are triggered by the filarial
antigen ultimately result in the activation of vascular endo-
thelial growth factors (VEGF), thus promoting lymph vessel
hyperplasia as a first step to lymphoedema development.
Wolbachia endosymbionts are major inducers of these
responses in vitro, and their depletion by doxycycline in LF
patients reduces plasma VEGF and soluble VEGF-receptor-
3 levels to those seen in endemic normals preceding pathol-
ogy improvement. The search for the immunogenetic basis
for LE could lead to the identification of risk factors and
thus, to prevention; and has so far led to the identification
of single-nucleotide polymorphisms (SNP) with potential
functional relevance to VEGF, cytokine and toll-like
receptor (TLR) genes. Hydrocele, a pathology with some
similarity to LE in which both lymph vessel dilation and
lymph extravasation are shared sequelae, has been found to
be strongly associated with a VEGF-A SNP known for
upregulation of this (lymph-)angiogenesis factor.
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INTRODUCTION
As a result of its heritable nature, much more is known
about the molecular basis of primary lymphoedema (LE)
in comparison with what is known about the aetiology
and pathophysiology of secondary LE – caused by trauma,
environmental factors (e.g. podoconiosis) or infection. The
single largest source of secondary LE is lymphatic filariasis
(LF), a disease caused by filarial nematodes (1).
An estimated 120 million people are infected with the
filarial nematodes Wuchereria bancrofti, Brugia malayi and
Brugia timori, which are the causative agents of LF, and 1Æ2
billion people are at risk of infection (2). The disease is
found in sub-Saharan Africa, India, Southeast Asia, parts
of South America, the Caribbean and the South Pacific.
Adult filarial parasites are sexually dimorphic and reside in
the lymphatic vessels, where they mate and produce thou-
sands of first-stage larvae [microfilaria (MF)] for up to
8 years. Mosquito vectors of the genera Aedes, Anopheles,
Culex or Mansonia are required for development of the
larvae into the human infective stage, and for transmission
to the human hosts. The vectors ingest MF during blood
meals. In the insect, the larvae develop into infective larvae
(L3), which are deposited on the skin of the humans during
subsequent blood meals. The larvae enter the body through
the wound made by the insect and undergo two more
moults to develop into adult worms, completing the cycle.
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clinical states with two major poles. One pole is repre-
sented by microfilaraemic patients with high parasite num-
bers and downregulated cell-mediated immune responses,
and the other by patients with LE or hydrocele (swelling
of the scrotal⁄groin area), who typically have few or no
parasites but vigorous specific immune reactions (3). LE
and hydrocele are not mutually exclusive and both involve
dilation of the lymphatic vessels and extravasation of fluid
from the vessels into the surrounding tissues, indicating a
shared pathogenesis. Among adult residents of endemic
areas, 12Æ5% have clinical manifestations of LE and 21%
of men have hydrocele (2), despite the fact that most indi-
viduals are presumably inoculated with L3 throughout life.
Both pathologies develop progressively and not all affected
individuals will progress to the most severe form of
pathology.
The Global Programme for the Elimination of Lympha-
tic Filariasis (GPELF) strives to eliminate LF as a public
health concern by 2020 by breaking transmission of the
MF to uninfected persons in the community (http://
www.filariasis.org) (4,5). The programme is conducted by
endemic countries with the help of the WHO and numer-
ous nongovernment organizations (NGOs) and undertakes
annual administration of antimicrofilarial drugs to eligible
members of the affected community, i.e. mass drug admin-
istration (MDA). In areas where the filarial nematode
Onchocerca volvulus is also endemic, the drug combination
of ivermectin (IVM, provided free to the WHO by Merck)
and albendazole (provided free to the WHO by Glaxo-
SmithKline) is administered. In areas where only W. ban-
crofti or Brugia spp. is present, diethylcarbamazine (DEC,
easily made in endemic countries) and albendazole (Glaxo-
SmithKline) are administered. Both IVM and DEC are
effective at killing the MF, but have limited, long-term
effects on the adult worms. For these reasons, the LYM-
FASIM programme, which models transmission and con-
trol of LF, predicts that administration of the drugs for at
least 8 years, assuming a coverage of >65% of the affected
population, is required (6).
With proper administration of the drugs and high
coverage participation in the programmes, it is possible to
achieve the desired block in transmission using MDA, as
has occurred in some affected countries (7). This assumes
that economic troubles or regional conflicts do not force
the movement of endemic populations from areas with
MDA coverage to areas without and that the worms do
not develop resistance to IVM or DEC. However, apart
from reducing new infection and therefore prevalence of
pathology, the main aim of MDA, these microfilaricidal
treatments do little for the 12Æ5% of infected individuals
who suffer from LE or the 21% who suffer from hydrocele,
as it is the death of the adult-stage worm that drives
pathology (8). Currently, the MDA programmes to elimi-
nate LF mainly offer hygiene and management courses to
patients with this pathology. While beneficial to various
extents, these methods do not greatly reverse the patho-
logy and therefore may hinder compliance (9). Under-
standing the immunological, molecular and genetic causes
of LE (and hydrocele) will help, as described below, to
develop better methods of identifying persons at risk, and
preventing⁄ameliorating these severe pathologies, thus
improving the daily lives of the affected individuals.
CLINICAL FINDINGS
The presence of adult worms in the lymph vessels and
lymph nodes is seen as a trigger for pathology. Histologi-
cally, there is little reaction around adult worms as long as
they are alive, but inflammation occurs when worms die,
either drug-induced or spontaneously (8). Granulomas
arise around those worms, characterized by macrophages
which develop into giant cells; as well as plasma cells,
eosinophils and neutrophils. The clinical symptom is
filarial fever that starts at the location of worm death and
typically leads to retrograde lymphangitis (painful, with
swelling) and lymphadenitis, which lasts for approximately
1 week during which the patient is immobilized. The
usually abrupt end of the fever is accompanied by scaling
off of the skin. While these episodes are clinically transient
in most infected individuals, they can be the starting point
for more chronic pathology leading to lymph fibrosis,
particularly in genetically predisposed individuals whose
immune system tends not to be appropriately downregu-
lated, but is rather stimulated (see below). However,
subclinical changes, such as lymph vessel dilation, are
almost invariably found in all infected individuals, e.g. in
the scrotal area of adult men infected with W. bancrofti
(Brugia does not reside in the scrotal area), where they
can be detected by ultrasonography (10) [grading of dila-
tion is described by Debrah et al. (11), see their Figure 9].
Lymph vessel dilation, not obliteration, is probably the
early event following antigenic stimulation, which takes
place while the adult worms are still alive, i.e. when off-
spring larvae are being released. Many of these larvae are
degenerate and will be taken up by phagocytic cells; it is
known that exposure of phagocytes to filarial antigens is
accompanied by triggering of the innate immune system
(12–14), with the release of not only pro-inflammatory
cytokines but also of molecules that promote lymphangio-
genesis, as detailed below. In addition to antigens from the
worm itself, those from its Wolbachia endosymbionts
appear to play a major role in pathogenesis, as their deple-
tion by doxycycline leads to a reduction of elevated
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the reduction of lymph vessel dilation [(11); see in detail
below].
The enlarged lymph vessels become less efficient at
transporting lymph from the periphery, which in the legs
is always oriented against gravity, making the system more
vulnerable to exogenous microorganisms, which may enter
the lymphatics following minor injuries that go unnoticed
in people without lymphatic disease. However, in people
with altered lymph vessels these secondary infections
trigger more inflammation⁄lymphangiogenesis, presenting
mainly as acute (bacterial) dermatolymphangioadenitis
(ADLA) (15–17). Insufficient fluid transport will lead to
fluid extravasation, particularly in the lower limbs, and
eventually to LE. Thus, exogenous microorganisms, in par-
ticular bacteria of the genus streptococci, are important
for the progression of the condition from subclinical lym-
phatic aberrations to LE, for which Dreyer and colleagues
(15) have defined seven stages (stages are also described in
Ref. (11)]. This is different from the second most frequent
form of pathology, hydrocele, i.e. accumulation of fluid
between the two folia of the tunica vaginalis in the scro-
tum. In this condition, lymph vessel enlargement and later
obliteration, probably including a chronic inflammatory
stimulus for the tunica vaginalis to secrete fluid between
the two folia, lead to the pathology independent of exo-
genous bacteria. To quantify improvement⁄worsening of
hydrocele, a staging system using ultrasonography of the
scrotal area has been developed (18).
IMMUNOLOGICAL FINDINGS
Neonatal tolerance has been recognized as a major factor
that prevents pathology following filarial infection (19).
This became evident when two scenarios in which non-
endemic persons exposed to filarial infection were analy-
sed. First, of the >38 000 US Naval personnel with LF
exposure in World War II in the South Pacific, >10 000
(27%) had clinical signs of filarial fever, while only 20 (!)
individuals actually became microfilaraemic. While this
was a rather short-term exposure and did not lead to
chronic pathology, permanent resettlement of people from
nonendemic into highly endemic areas did, as observed in
Indonesia (20); this was also accompanied with a high
prevalence of clinical signs and low prevalence of micro-
filaraemia. In sharp contrast, the majority of individuals
born in endemic areas are chronically infected and many
of them are microfilaraemic, without clinical signs of
pathology. In long-term studies, the tendency to develop
asymptomatic infection with high parasite loads and
microfilaraemia was associated with the status of being born
from microfilaraemic mothers (21); this earlier ground-
breaking study from a Pacific island has recently been
confirmed by a prospective analysis from Kenya (19,22).
The molecular mechanisms associated with this neonatal
tolerance were found to be associated with markers of
immunosuppression and⁄or immune tolerance to filarial
antigens. However, not all individuals born in endemic
areas acquire this status. This is probably due to a mixture
of environmental factors (transmission level, co-infections)
and genetic propensity (see below). The general picture is
that lack of filarial-specific T-cell proliferation and pro-
duction of IL-10 or TGF-b is associated with the permis-
sive status, while a prospectively lower likelihood to
become infected in an endemic area correlates with higher
levels of IFN-c, IL-5 and IL-13 (19,22,23), and individuals
with pathology may in addition show a tendency to react
with higher IL-17 responses to exogenous stimuli (24). In
accordance with the finding that IL-10 promotes IgG4
responses (25), whereas Th2 reactions induce IgE, patients
with the permissive status show higher levels of IgG4 than
do those with pathology (3).
Raised levels of IL-6 and IL-8 emerged as markers of
acute as well as chronic disease in a large-scale study in
India (26). Whether this is the cause or rather the conse-
quence of chronic disease is not fully clear. In either case,
the release of markers of the innate immune response is at
least in part due to the reactions against bacterial prod-
ucts, i.e. those from the Wolbachia endosymbionts, as
could be shown in vitro and in vivo in several studies
(12–14). In support of the innate markers being the cause
rather than the consequence⁄epiphenomenon of pathology,
they decrease in serum following depletion of Wolbachia
by treatment with doxycycline (27), and this precedes
improvement of pathology such as lymph vessel dilation
(see the section on Wolbachia below).
Common sequelae of the stimulation of the innate
response include the production of vascular endothelial
growth factors, e.g. by macrophages [reviewed in Ref.
(28)]. These factors are elevated following LF infection,
with different levels of expression in the different disease
forms (see below). They seem to be instrumental in the
stimulation of lymph vessel growth, which is the first step
in a series of events that leads to the different lymphatic
pathologies, described below.
Recent studies focusing on molecular mechanisms regu-
lating blood and lymphatic vessel growth (29–31) have
shown that vascular endothelial growth factors (VEGF)
control angiogenesis and lymphangiogenesis in humans
(32–35). The VEGF family comprises five members (36),
including VEGF-A, a potent regulator of normal and
abnormal angiogenesis (37). Over-expression of VEGF-A
in the skin of mice results in increased vascular density,
enhanced leucocyte adhesion, and tissue infiltration and
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the migration of endothelial cells and increases vascular
permeability and lymph endothelial proliferation, but at
higher concentration than that of VEGF-A (39). Over-
expression of VEGF-C in the skin of transgenic mice
results in lymphatic endothelial proliferation and dilation
of lymph vessels (40). Signals for endothelial cells are med-
iated through VEGFR-2 in blood vascular endothelial
cells, and generally via VEGFR-3 in the lymphatic endo-
thelial cells (29,41).
The expression of VEGF-A and VEGF-C has been
shown to be up-regulated by pro-inflammatory cytokines,
such as IL-1b, TNF and IL-17 (42), suggesting that pro-
inflammatory cytokines affect the lymphatic vessels via
VEGF-A and VEGF-C (43,44). Major inducers of pro-
inflammatory mediators are the Wolbachia essential endo-
symbionts of filariae.
ROLE OF WOLBACHIA
It has been known for more than 30 years that filarial
nematodes contain the endosymbiotic bacteria Wolbachia
of the order Rickettsiales (45). These endosymbiotic bacte-
ria are found in the hypodermis of male and female worms,
in the oocytes, embryos and larval stages (46). As in many
animal filarial species, these endobacteria are present in
human filariae including W. bancrofti, Brugia species and
O. volvulus (4,47–49), with the exception of a few species
such as Loa loa (50,51). The discovery of the essential role
of Wolbachia in worm fertility and survival has resulted in
the development of an antifilarial chemotherapy with
doxycycline, which depletes Wolbachia from the worms and
leads to long-term worm sterility (47,48) and macro-
filaricidal activity in both bovine (52) and human oncho-
cerciasis (53) as well as human LF (11,54,55).
In addition to the possible role of Wolbachia as a chemo-
therapy target, it has become clear that Wolbachia anti-
gens can stimulate host immune responses that may be
associated with development and progression of pathogen-
esis of filarial diseases. Low level exposure of the immune
system to Wolbachia stimuli could occur via the uptake of
degenerate larvae released by the females by phagocytic
cells. Upon death of the MF, e.g. after DEC or IVM
treatment, or natural death of an adult worm, the immune
system would be exposed to a large amount of pro-inflam-
matory stimuli, including large numbers of Wolbachia. In
a laboratory model of onchocerciasis for instance, Wolba-
chia were shown to mediate neutrophil infiltration and ker-
atitis (blindness) when a worm extract including Wolbachia
antigens was injected into the eyes of mice (13,56). Such a
reaction is not seen with Wolbachia-depleted extract
because during antibiotic treatment, the dying⁄dead endo-
bacteria are cleared from the worm probably via a normal
mechanism for maintaining the symbionts at levels accept-
able to nematode survival. This clearance, which occurs
slowly, presumably also prevents the exposure of the
immune system to endobacterial ligands either by degra-
dation or by modification.
Wolbachia have been shown to stimulate pro-inflamma-
tory cytokines, such as TNF, IL-1b and IL-6, and nitric
oxide (12–14), which are known to upregulate the expres-
sion of VEGF-C (43,44). This stimulation is mainly sig-
nalled via TLR 2, which in other inflammatory diseases is
known to mediate the upregulation of VEGFs (57). This
raises the possibility that pro-inflammatory cytokines such
as TNF and IL-1b induced by Wolbachia could affect lym-
phatic vessels by induction of VEGFs. Indeed, elevated
serum levels of VEGF-A and endothelin-1 (58) as well as
VEGF-C and VEGFR-3 (11) were found in filaria-infected
patients.
It is therefore conceivable that any therapeutic interven-
tion that causes reduction of lymphangiogenic factors may
lead to reduction of dilated lymphatic vessels. Evidence
was provided in a recent study, which showed that
increased levels of VEGF-C were associated with infection,
while VEGFR3 levels were yet significantly higher in LE
than in other conditions of LF infection (11). Doxycycline
treatment not only reduced Wolbachia copy numbers by
95% in W. bancrofti-infected patients but also reduced the
plasma levels of VEGF-C⁄sVEGFR-3, resulting in amelio-
ration of dilated lymphatic vessels and improvement in the
conditions of LE patients. Affected legs of all the doxy-
cycline-treated patients reverted significantly to a lower
stage at 12 months post-therapy, while the condition of
the placebo-treated patients stayed the same or increased
to a higher stage (11). However, the improvement was
more pronounced in patients with initial lower stages of
LE (stages 1–3) than those with higher stages [stages 4–6;
staging according to Dreyer et al. (59)]. Importantly, the
reduction of the VEGF-C⁄sVEGFR-3 preceded the ame-
lioration of the dilated lymphatic vessels and LE. Because
all participants received IVM 4 months after doxycycline
treatment to clear the MF from their blood, it was con-
cluded that this effect was attributable to doxycycline, and
thus associated with reduction of Wolbachia.
Data suggest a similar phenomenon for hydrocele being
associated with lymphangiogenic markers, specifically
VEGF-A (54). In hydrocele patients, targeting the Wolba-
chia endosymbionts by doxycycline led to a reduction in
plasma levels of VEGF-A, with consequential ameliora-
tion of the size of hydrocele (60). Importantly, the amelio-
ration and VEGF-A reduction was observed in patients
who were circulating filarial antigen (CFA)-positive (i.e.
actively infected), but not in doxycycline-treated patients
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data are in agreement with the hypothesis that progression
of infection to hydrocele may be contributed to by
the over-expression of vascular and lymphangiogenic
factors such as VEGF-A, which promotes extravasation of
fluid and plasma proteins, including fibrin from the blood
vessels into surrounding tissues. Secretion of VEGF-A
molecules in the scrotal region of hydrocele patients could
be responsible for: (i) extravasation and accumulation of
fluids, plasma, lymph, etc. from the blood and lymphatic
vessels into the scrotal region, resulting in the formation
of hydrocele, chylocele and lymphocele; (ii) formation of
nodules in hydrocele patients which are usually observed
just before hydrocele development when DEC is adminis-
tered (61). The formation of these nodules might result
from the death of adult worms due to DEC treatment,
which would in turn lead to liberation of VEGF-A, in
part due to release of Wolbachia. However, in a study con-
ducted by Esterre et al. (58), the level of serum VEGF
was shown to remain the same in patients with bancrof-
tian filariasis after DEC treatment. While more research
will be needed to elucidate the reasons for this lack of
VEGF increase, one might conclude that this may be due
to the fact that DEC treatment has no effect on bacteria
(neither Wolbachia nor exogenous species that augment
and maintain the pathology of LE (15), and therefore has
no effect on pro-inflammatory cytokines that regulate this
VEGF family, although it does partially reduce adult
worm levels.
Although further investigations are needed to elucidate
the mechanism of doxycycline in reducing lymphangiogenic
factors and lymphatic vessel dilation, our data suggest that
plasma levels of VEGF-A⁄VEGF-C⁄sVEGF-R3 may
correlate with disease progression in LF leading to LE and
hydrocele, and hence, might be used as prognostic indicators
of an increased risk of LF pathology before it manifests.
The data also indicate that filarial pathology may be caused
by over-expression of lymphangiogenic factors as a result of
stimulation of pro-inflammatory cytokines induced by the
filarial and Wolbachia antigens in the lymphatic vessels. In
further support of this in an animal model of filariasis,
VEGF gene expression following infection with L3 can be
readily detected (Specht S. and Hoerauf A., unpublished
data), suggesting an important role of VEGFs for the estab-
lishment of L3 in the host’s body.
ROLE OF THE NEMATODE
In addition to their endobacteria, filarial nematodes them-
selves are a source of ligands which can induce an immune
response that might lead to the development of LE. As has
been shown, macrophages and monocytes produce pro-
inflammatory cytokines in response to protein extract from
Wolbachia-depleted B. malayi or Acanthocheilonema viteae,
a filarial nematode without endosymbionts (14,56). How-
ever, comparison of the Wolbachia-containing extract with
the reaction produced by Wolbachia-containing extract
reveals that the level of induction from the nematode is
greatly reduced . Such a reduced reaction makes sense for
the long-term survival of the nematodes as it is known that
MF induce a hyporesponse (23,62–65). Two studies that
examined the effect of doxycycline treatment prior to antif-
ilarial treatment also demonstrated that the nematodes
themselves can induce a pro-inflammatory response. In
these studies, adverse reactions to IVM or DEC treatment
were monitored in patients who were given doxycycline or
placebo prior to treatment. When MF were depleted of
Wolbachia, adverse reactions still occured, but they were
less severe (27,66). Thus, under normal conditions when
the endobacteria are contained within their nematode hosts
and separated from the immune system, few cytokines that
could induce VEGF or other factors involved in LE deve-
lopment are released. However, upon death of the MF or
adult worms, large amounts of immune stimulatory ligands
are quickly released, including the highly active Wolbachia
components, which may then induce a strong pro-
inflammatory response.
IMMUNOGENETICS
As explained above, host immune responses are required
for controlling worm load at the level of both circulating
larvae and adult worms in the mammalian host. These
factors can then induce the expression of other genes, such
as VEGFs, that are hypothesized to contribute to LE. The
immune responses differ between individuals who have
pathology and those who do not, even if the parasitologi-
cal parameters are similar. One explanation for different
responses of patients is that single-nucleotide polymor-
phisms (SNPs) alter the expression of or the activity of
immune factors, leading to the broad range of disease
manifestations that can develop.
Studies have shown that susceptibility to infection and
parasite load cluster in families (67,68). One of the first
studies dealing with genetics as a factor for susceptibility
to filarial infection was carried out in a Polynesian popu-
lation infected with W. bancrofti. The results showed that
52% of the children whose parents both had LF were also
infected. This dropped to 18% when just one of the par-
ents had LF, and was 0% when neither parent had LF.
A gene frequency of 0Æ82 was estimated for the unidenti-
fied allele in this study (67). Two studies in Indonesia have
also shown family clustering of B. malayi infection. Both
studies measured microfilaraemia and antibodies to
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found to cluster in families, independent of household and
environmental factors (69,70).
There are also published studies on the genetic basis for
developing LE pathology in lymphatic filariasis. Two stud-
ies in Haiti dealing with the genetic basis for developing
LE found that 42% of the patients with LE in at least one
leg also had parents with LE. The incidence of multiple
cases of LE was also clustered in families (71,72). Studies
on the exact genetic factors that lead to families having a
greater incidence of filariasis and LE have only recently
begun by dealing with SNPs.
Several studies have described an association of SNPs
with either susceptibility to disease or pathology in LF.
Choi et al. have shown in a study in South India that
patients are more susceptible to W. bancrofti infection if
they are homozygous for the allele that is responsible for
lower levels of chitotriosidase (CHIT1), a protein found in
phagocytic cells (73). Interestingly, no association of sus-
ceptibility to infection with CHIT1 was found in Papua
New Guinea (74), demonstrating the importance of geno-
typing populations from different endemic areas.
Recently, we have published a case–control study that
examined the role of VEGF-A SNPs in hydrocele, pathol-
ogy with some similarity to LE in that both the dilation
of the lymph vessels and extravasation of lymph into the
surrounding tissues are a shared sequela. In the study,
three promoter SNPs were tested for association with
hydrocele. The genotype frequency of the )460 C⁄T poly-
morphism differed significantly between patients with and
without hydrocele. The allele C, known to upregulate
VEGF-A production, was significantly higher in hydrocele
patients (74%) than in nonhydrocele LF patients (4%).
A positive correlation was also observed between plasma
concentrations of VEGF-A and the stage of hydrocele,
providing evidence that the )460 C polymorphism is a
novel genetic risk factor for hydrocele development in
lymphatic filariasis (18).
While similar studies have not yet been published on
immunogenetic factors and their role in LE, the preceding
SNP results support a causal role of patient genetics in
LF development and specifically identify immunological
markers having a causal role in filarial pathology. Similar
to what has been shown for primary LE (1,75), there is a
genetic component to the development of secondary LE in
response to filarial infections. To date, most publications
have used a candidate gene approach to find the associa-
tion of SNPs with disease susceptibility or pathology. Our
own studies have found an association of IL-18 and TLR-
4 SNPs with LE in W. bancrofti and B. timori infections.
Additionally, we have found an association of IL-4 recep-
tor and TGF-beta SNPs with microfilaraemia and latent
infection, respectively (Debrah A., Pfarr K., Hoerauf A.,
Albers A., Becker T., Mand S., unpublished observations).
VEGF-A is also likely to play a role in LE development
because of its role in lymphangiogenesis (60), as has been
shown for hydrocele (18). The next step will be to conduct
a genome-wide scan to identify loci and genes associated
with LE and hydrocele. To this end, we have completed
recruitment of unrelated patients in Ghana for a case–
control study.
ONGOING STUDIES AND FUTURE
ASSESSMENTS
Knowledge of genomic loci linked to parasite loads and
pathology would help in the understanding of pathogene-
sis which could lead to the development of strategies,
beyond the supportive care advocated for hydrocele and
LE (11,18), to ameliorate pathology in the 40 million peo-
ple affected by LE. Such strategies would in turn help in
compliance with the current drug therapies to interrupt
transmission, as the inability to treat the physical pathol-
ogy is a key factor in noncompliance (9). Knowing genetic
markers for LE and hydrocele could also provide a way to
identify persons at risk before pathology is evident and
might become the basis for development of a screening
test that, in the case of LE, which develops early in life,
might be applied to school-aged children.
From the studies using doxycycline treatment, it is
clear that more research is needed to unravel the associa-
tions between Wolbachia, lymphangiogenic molecules,
lymphatic dilation and pathology development. For doxy-
cycline to exert its ameliorating activity by targeting Wol-
bachia, it is mandatory that the targets, i.e. adult worms,
MF or at least incoming L3⁄4 larvae, are present in the
host’s body. Although our results indicate that the deple-
tion of Wolbachia was the most probable cause of the
reduction in LE, it could not be ruled out that doxycy-
cline had another target, either the host lymphatic endo-
thelial cells, or another bacterial or fungal infection,
which led to these astounding results. It is important,
therefore, to investigate whether the targeting of either
Wolbachia or other opportunistic bacteria is the essential
mechanism for the improvement of LE observed. To
ascertain this fact, there is an ongoing study (ISRCTN
No. 90861344) with three different treatment regimens:
one group treated with doxycycline, targeting Wolbachia
and other exogenous bacteria; one group treated with
amoxicillin, targeting only exogenous bacteria with no
effect on Wolbachia and the third group treated with
placebo. To date, there has been significant amelioration
in the doxycycline vs. placebo groups and also between
doxycycline and amoxicillin groups, while there was no
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groups, suggesting that targeting of Wolbachia by doxycy-
cline might be more beneficial than targeting potential
opportunistic exogenous bacteria. Final assessments are
still pending, but these trials show that there is a new
hope for LE and hydrocele patients.
Another factor to consider is the direct effects of doxy-
cycline that could lead to reduced pathology. Recently,
Fainaru et al. showed that oral doxycycline prevents
VEGF-mediated vascular permeability and IL-2-induced
pulmonary oedema (76). At the molecular level, doxycy-
cline appeared to act on the adherence junction in the vas-
culature with increased expression of VE-cadherin, thus
maintaining the cell junctions between endothelial cells
and reducing their permeability.
Antiwolbachial therapy, especially with doxycycline,
would be more effective than therapy with other antifilarial
drugs because it depletes Wolbachia which leads to a
reduction in pro-inflammatory stimuli that in turn can
induce VEGF; eventually kills adult worms, removing
another source of pro-inflammatory stimuli; and may
directly act on the lymphatic cells to maintain cell junc-
tions and prevent extravasation of fluid into the surround-
ing tissue. Hence, doxycycline treatment has a good
chance to be the first chemotherapeutic approach to
address lymphatic pathology, especially in patients with
early-stage LE which is easier to reverse. Patients with LE
suffer considerably, and may reasonably be expected to
take doxycycline for 6 weeks without the need of a directly
observed treatment (DOT). Thus, doxycycline is a drug
immediately available to physicians that will allow them to
better treat their patients who come to them with the goal
of improving their physical condition.
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